Pacira Biosciences
PCRX
Pacira Biosciences (PCRX) - P/B ratio
P/B ratio as of April 2024 : 1.41
According to Pacira Biosciences
's latest financial reports the company has a price-to-book ratio of 1.41.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Pacira Biosciences - P/B ratio (from 2011 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 1.80 | -21.22% |
| 2022-12-31 | 2.29 | -37.71% |
| 2021-12-31 | 3.67 | -12.53% |
| 2020-12-31 | 4.20 | -21.57% |
| 2019-12-31 | 5.35 | -3.12% |
| 2018-12-31 | 5.52 | -16.69% |
| 2017-12-31 | 6.63 | 20.11% |
| 2016-12-31 | 5.52 | -57.42% |
| 2015-12-31 | 13.0 | -30.82% |
| 2014-12-31 | 18.7 | -60.05% |
| 2013-12-31 | 46.9 | 441.7% |
| 2012-12-31 | 8.65 | 180.3% |
| 2011-12-31 | 3.09 | |
| 2010-12-31 | N/A | |
| 2009-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Omeros Corporation OMER | -13.1 | -1,027.79% | 🇺🇸 USA |
 Heron Therapeutics HRTX | -10.9 | -874.80% | 🇺🇸 USA |
 Cara Therapeutics
CARA | 0.6514 | -53.73% | 🇺🇸 USA |